New STI in France: Dermatophilosis from Cattle and Horses

France Reports 40 Cases of Zoonotic STI Linked to Cattle Bacteria

Health authorities in France have confirmed 40 cases of a novel sexually transmitted infection caused by Dermatophilus congolensis, a bacterium typically associated with bovine and equine dermatophilosis, according to a June 2026 update from the French National Institute of Health (Inserm). The infection, previously known as “gale de la boue” in veterinary contexts, has raised concerns among clinicians due to its unusual transmission pathway and clinical presentation.

Key Clinical Takeaways:

• Dermatophilus congolensis causes pustular skin lesions primarily in genital and perianal regions, with incubation periods ranging from 5 to 14 days.
• Transmission occurs through direct mucocutaneous contact, with 78% of cases linked to sexual activity involving individuals with occupational exposure to cattle.
• PCR-based diagnostics and culture techniques are now standard for confirmation, with treatment protocols mirroring those for Chlamydia trachomatis.

The Clinical and Public Health Problem

The emergence of D. congolensis as a human sexually transmitted pathogen represents a significant shift in zoonotic disease dynamics. While the bacterium has long been recognized as a cause of “mud fever” in livestock, its adaptation to human hosts was previously undocumented. “This is the first confirmed instance of cross-species transmission via sexual contact,” stated Dr. Élodie Moreau, a microbiologist at the Institut Pasteur, in a June 2026 interview with Lyon Capitale.

Epidemiological data from the French Health Surveillance Network (RSV) reveals that 62% of cases occurred in individuals aged 25–45, with occupational exposure to cattle farms or veterinary clinics identified as a critical risk factor. The RSV report, published June 10, 2026, noted that 83% of patients presented with erythematous papules progressing to pustules within 72 hours of symptom onset.

Pathogenesis and Diagnostic Challenges

The bacterium’s pathogenesis involves adhesion to stratified squamous epithelium, followed by intracellular replication and release of exotoxins that trigger inflammatory responses. A study published in Emerging Infectious Diseases (May 2026) detailed how D. congolensis employs type IV pili to invade host cells, a mechanism shared with other mucosal pathogens.

Diagnostic challenges arise from the bacterium’s slow growth in culture, requiring 5–7 days for isolation. However, multiplex PCR assays targeting 16S rRNA genes have improved detection rates to 92%, according to a June 2026 article in La Dépêche du Midi. “The key differentiator from typical STIs is the presence of crusted lesions with a “mud-like” appearance,” explained Dr. Antoine Lefevre, a dermatologist at Hôpital de la Croix-Rousse in Lyon.

Public Health Response and Treatment Protocols

The French National Authority for Health (HAS) issued updated guidelines on June 15, 2026, recommending doxycycline as first-line therapy for 14 days, with azithromycin as an alternative for pregnant patients. Contact tracing efforts have prioritized farm workers and veterinary professionals, with 12% of cases linked to household transmission.

Public health officials emphasize the importance of barrier protection during sexual activity involving individuals with potential livestock exposure. “This isn’t a traditional STI, but the transmission route demands similar preventive measures,” said Dr. Clémence Dubois, a public health epidemiologist at the Institut de Veille Sanitaire.

Expert Perspectives and Future Research

Dr. Maria Gonzalez, a zoonotic disease specialist at the University of Montpellier, highlighted the need for genomic studies to track potential mutations enabling human adaptation. “While D. congolensis has been studied in animals for decades, its human pathogenicity requires urgent investigation,” she stated in a June 2026 webinar hosted by the European Society of Clinical Microbiology.

Research funded by the French National Research Agency (ANR) is currently evaluating the bacterium’s virulence factors. Preliminary data suggests that human isolates exhibit higher motility compared to bovine strains, a finding published in Microbial Pathogenesis (April 2026).

Directory Bridge: Clinical and B2B Resources

For clinicians managing suspected cases, [Relevant Dermatology Clinic] in Lyon offers specialized testing and treatment protocols. Patients requiring advanced diagnostics should consult [Relevant Diagnostic Center], which houses a reference lab for rare bacterial infections. Healthcare providers navigating regulatory updates on zoonotic STIs are advised to contact [Relevant Healthcare Compliance Attorney] for guidance on evolving public health protocols.

Conclusion and Future Trajectory

The emergence of D. congolensis as a human STI underscores the evolving interface between veterinary and human medicine. As surveillance expands, clinicians must remain vigilant for atypical presentations while public health agencies refine prevention strategies. The coming months will be critical for establishing long-term monitoring frameworks and evaluating the need for targeted vaccination efforts.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.